1092 related articles for article (PubMed ID: 27856181)
21. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
22. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
23. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
24. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of the TREK-1 K2P potassium channels in prostate cancer.
Zhang GM; Wan FN; Qin XJ; Cao DL; Zhang HL; Zhu Y; Dai B; Shi GH; Ye DW
Oncotarget; 2015 Jul; 6(21):18460-8. PubMed ID: 25962960
[TBL] [Abstract][Full Text] [Related]
26. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.
Asim M; Massie CE; Orafidiya F; Pértega-Gomes N; Warren AY; Esmaeili M; Selth LA; Zecchini HI; Luko K; Qureshi A; Baridi A; Menon S; Madhu B; Escriu C; Lyons S; Vowler SL; Zecchini VR; Shaw G; Hessenkemper W; Russell R; Mohammed H; Stefanos N; Lynch AG; Grigorenko E; D'Santos C; Taylor C; Lamb A; Sriranjan R; Yang J; Stark R; Dehm SM; Rennie PS; Carroll JS; Griffiths JR; Tavaré S; Mills IG; McEwan IJ; Baniahmad A; Tilley WD; Neal DE
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26657335
[TBL] [Abstract][Full Text] [Related]
27. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of transformer 2β expression in prostate cancer.
Diao Y; Wu D; Dai Z; Kang H; Wang Z; Wang X
Int J Clin Exp Pathol; 2015; 8(6):6967-73. PubMed ID: 26261585
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
[TBL] [Abstract][Full Text] [Related]
31. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
32. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
33. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.
Zhang Y; Yuan Y; Liang P; Zhang Z; Guo X; Xia L; Zhao Y; Shu XS; Sun S; Ying Y; Cheng Y
Oncotarget; 2017 Jul; 8(28):45459-45469. PubMed ID: 28525372
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-132/212 Upregulation Inhibits TGF-β-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4.
Fu W; Tao T; Qi M; Wang L; Hu J; Li X; Xing N; Du R; Han B
Prostate; 2016 Dec; 76(16):1560-1570. PubMed ID: 27527117
[TBL] [Abstract][Full Text] [Related]
36. High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival.
Zhang Y; Yang WK; Wen GM; Tang H; Wu CA; Wu YX; Jing ZL; Tang MS; Liu GL; Li DZ; Li YH; Deng YJ
Mol Genet Genomic Med; 2019 Nov; 7(11):e908. PubMed ID: 31513357
[TBL] [Abstract][Full Text] [Related]
37. TUG1 promotes the development of prostate cancer by regulating RLIM.
Guo BH; Zhao Q; Li HY
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
[TBL] [Abstract][Full Text] [Related]
38. MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer.
Xiang J; Bian C; Wang H; Huang S; Wu D
J Exp Clin Cancer Res; 2015 Jan; 34(1):8. PubMed ID: 25636908
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
40. Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma.
Che JP; Li W; Yan Y; Liu M; Wang GC; Li QY; Yang B; Yao XD; Zheng JH
Int J Clin Exp Pathol; 2013; 6(11):2300-11. PubMed ID: 24228091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
